MARKET

SNGX

SNGX

Soligenix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.000
+0.060
+3.09%
Closed 17:22 09/18 EDT
OPEN
1.960
PREV CLOSE
1.940
HIGH
2.040
LOW
1.930
VOLUME
380.45K
TURNOVER
--
52 WEEK HIGH
3.540
52 WEEK LOW
0.8500
MARKET CAP
59.69M
P/E (TTM)
-2.8567
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of nonclinical results characterizing filovirus protein antigens
PR Newswire · 5d ago
SNGX: Update and Q&A on COVID-19 Vaccine Candidate CiVax™…
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Update on COVID-19 Vaccine Candidate CiVax™ On September 10, 2020, Soligenix, Inc. (NASDAQ:SNGX) held a webinar to provide an update on the COVID-19 vaccine landscape and the company’s COVID-19 vaccine candidate CiVax™
Zacks Small Cap Research · 09/11 13:41
Soligenix Announces Investor Webcast Event And Presentation Today Titled 'Advantages of the CiVax Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine'
PRINCETON, N.J., Sept. 10, 2020 /PRNewswire/ --Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare
Benzinga · 09/10 11:34
Soligenix Invited to Present at Upcoming Virtual Investor Conferences
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD
PR Newswire · 09/09 12:00
How Much Is Soligenix's (NASDAQ:SNGX) CEO Getting Paid?
Christopher Schaber became the CEO of Soligenix, Inc. (NASDAQ:SNGX) in 2006, and we think it's a good time to look at...
Simply Wall St. · 09/03 20:18
Soligenix to host investor webcast
On September 10, beginning at 4 ET (webcastlink), Soligenix (SNGX) will be hosting an investor webcast event on the use of its thermostabilized glycoprotein vaccine platform for the development of
Seekingalpha · 09/03 12:41
Soligenix Announces Investor Webcast Event: Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be hosting an Investor Webcast Event Thursday, September 10, 2020
PR Newswire · 09/03 11:30
SNGX: Multiple Upcoming Catalysts
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 DOM-INNATE Results in 4Q20 Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 DOM-INNATE ( D usquetide treatment in O ral M ucositis – by modulating INNATE immunity) trial of SGX942 in the treatment
Zacks Small Cap Research · 08/17 14:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNGX stock price target is 6.31 with a high estimate of 12.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 2.65M
% Owned: 8.87%
Shares Outstanding: 29.85M
TypeInstitutionsShares
Increased
8
106.17K
New
12
91.70K
Decreased
3
359.74K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Chief Executive Officer/President/Director
Christopher Schaber
Chief Financial Officer/Senior Vice President/Secretary
Jonathan Guarino
Senior Vice President/Chief Scientific Officer
Oreola Donini
Senior Vice President
Richard Straube
Independent Director
Gregg Lapointe
Independent Director
Diane Parks
Independent Director
Robert Rubin
Independent Director
Jerome Zeldis
Independent Director
Anthony Lapointe
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average SNGX stock price target is 6.31 with a high estimate of 12.00 and a low estimate of 2.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNGX
Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Soligenix Inc stock information, including NASDAQ:SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.